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OBJECTIVE—To investigate the clinical efﬁcacy of zoledronic acid in patients with diabetes
and acute Charcot neuroarthropathy.
RESEARCH DESIGN AND METHODS—Thirty-nine consecutive patients were ran-
domly assigned to placebo or three intravenous infusions of 4 mg zoledronic acid. The primary
outcome was clinical resolution of acute Charcot neuroarthropathy determined by total im-
mobilization time (casting plus orthosis).
RESULTS—At baseline, there was no signiﬁcant difference between the randomly assigned
groups with respect to Charcot disease activity or other baseline values. In the zoledronic acid
group,themedian time for total immobilizationwas27weeks(range10–62), and intheplacebo
group it was 20 weeks (20–52) (P = 0.02).
CONCLUSIONS—Zoledronic acid had no beneﬁcial effect on the clinical resolution of acute
Charcotneuroarthropathyintermsoftotalimmobilizationtime.Itispossiblethatitmayprolong
the time to clinical resolution of Charcot neuroarthropathy.
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C
harcot neuroarthropathy is a rare
but devastating complication of di-
abetes, with an incidence of 0.1–
0.3% in patients with diabetes (1,2).
The pathogenesis of acute Charcot neuro-
arthropathy remains unclear. It is hypothe-
sizedthattheactivationoftheinﬂammatory
cascade (via receptor activator of nuclear
factor k-B ligand [RANKL] signaling path-
way) at the onset of acute Charcot neuro-
arthropathy leads to the activation of
osteoclasts and subsequent bone and joint
destruction(3–5).Severalpharmacological
adjuncts have been reported to be bene-
ﬁcial in acute Charcot neuroarthropathy
(6–10). This double-blind, randomized
controlled trial investigates the efﬁcacy of
zoledronic acid (bisphosphonate) in pa-
tientswithacuteCharcotneuroarthropathy.
RESEARCH DESIGN AND
METHODS—The aim of the study was
to evaluate whether three intravenous
infusions of4 mg zoledronic acid (Zometa,
administered in 1-month intervals) would
accelerate clinical resolution of acute
Charcot neuroarthropathy in the midfoot.
The study protocol was evaluated by the
local ethics committee (R01165M), and
the study was performed without indus-
trial sponsorship. The trial was conducted
in accordance with the Declaration of
Helsinki, and all patients gave their writ-
teninformedconsent.Patientswithsevere
renal insufﬁciency (serum creatinine
.400 mmol/L) or previous bisphospho-
nate treatment were excluded from the
study.
The diagnosis of acute midfoot Char-
cotneuroarthropathywasbasedonclinical
examination and radiological ﬁndings.
Clinical criteria for acute Charcot neuro-
arthropathy included the presence of a
warm, swollen foot with erythema over
thewarmestareaofthefoot.Anincreaseof
$2°C (infrared thermometer) compared
w i t ht h es a m es i t eo nt h ec o n t r a l a t e r a l
foot was taken to indicate active Charcot
neuroarthropathy. All patients with a sus-
picion of Charcot neuroarthropathy un-
derwent plain radiographs and magnetic
resonance imaging of the affected foot.
Themainmagneticresonanceimagingcri-
teria for Charcot neuroarthropathy were
periarticular focal bone marrow odema,
absent sinus tracts or soft-tissue ﬂuid col-
lections, and preservation of periarticular
subcutaneous fat (11).
Patients initially were treated con-
servatively with a non–weight-bearing,
below-the-knee contact cast. When the
skin temperature difference between feet
was 1–2°C and no other clinical signs of
active Charcot processes were present,
partial weight bearing was allowed and a
ﬁxed ankle–foot orthosis was applied.
The temperature differences and the clin-
ical signs of reactivation of the Charcot
process were evaluated in 2–4-week in-
tervals until the resolution stage was
reached. The resolution stage was as-
sessed as a temperature difference of
,1°C during the last 30-day period
with no evidence of erythema or edema.
Atthispoint,immobilizationwasdiscon-
tinued, and full weight bearing was al-
lowed with accommodative shoe wear
(total-contact insoles or custom-made
shoes with rocker soles).
A total of 39 consecutive Caucasian
patients were recruited into the study.
Patients were assessed at baseline and at
2–4-week intervals for the ﬁrst 3 months
a n da t6 ,9 ,a n d1 2m o n t h st h e r e a f t e r .
Four patients were excluded from the
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BRIEF REPORTﬁnal analysis because of a protocol viola-
tion(threepatients)ortheneedforsurgical
procedure (one patient had a below-the-
knee amputation) during the immobiliza-
tion period. Thirty-ﬁve patients completed
the 1-year follow-up (Supplementary
Fig. 1).
Continuous variables are expressed
as the median and range. Between-group
comparisons of continuous variables at
each time point were analyzed with the
Mann-Whitney U test as a result of
skewed distribution. Data were analyzed
with use of the x
2 test and Fisher exact
test, as appropriate. Tests were two-
tailed, with use of a critical value of 0.05.
RESULTS—At baseline, there was no
signiﬁcant difference between groups
(Table 1). In the zoledronic acid group
(group Z), the median for total immobili-
zation time was 27 weeks (10–62 weeks),
and in the placebo group (group P), the
median for total immobilization time was
20 weeks (20–52 weeks) (P = 0.02). Feet
in group Z were immobilized in a cast
for a median of 15 weeks (0–28 weeks)
andingroupPfor12weeks(0–20weeks)
(P = 0.13). Time of immobilization in
orthosis was 15 weeks (7–40 weeks) for
g r o u pZa n d1 0w e e k s( 4 –32 weeks) for
group P (P = 0.05). Total weight bearing
with total-contact insoles or custom-made
shoes with rocker soles was permitted
after a median of 28 weeks (10–64 weeks)
for group Zandafter amedian of24weeks
(14–52weeks) for group P (P =0 . 1 3 ) .O n e
relapse of Charcot neuroarthropathy
was diagnosed in each group during
the12-monthfollow-upperiod.Noserious
adverse events were recorded.
CONCLUSIONS—Previous reports
(6–9) have indicated a beneﬁcial effect
of bisphosphonates on the reduction in
bone turnover markers in Charcot neuro-
arthropathy, but the clinical efﬁcacy of
these drugs remains controversial. How-
ever, this study did not suggest any ben-
eﬁcial effect of zoledronic acid on the
clinical resolution of acute Charcot neu-
roarthropathy. To the contrary, patients
treated with zoledronicacidrequiredlon-
ger immobilization time compared with
the placebo group (P = 0.02). The main
problemsofthisstudyarearelativelysmall
sample size (statistically underpowered), a
wide variation in immobilization times,
and an inability to monitor concordance
to the non–weight-bearing protocol.
Fifteen years ago, the ﬁrst medical
trails were performed to investigate
whether osteoclast inhibitors (bisphos-
phonates) had an effect on the Charcot
neuroarthropathic disease process (6).
Promising results were reported with
alendronate and pamidronate, and most
recently with calcitonin (nonbisphospho-
nate osteoclast inhibitor) (6–10). A clear
reduction in bone turnover markers was
reported in these trials. This is an ex-
pected pharmacological effect of these
drugs, and the clinical beneﬁto ft h i sr e -
mains unclear.
Theactivationofosteoclastsandbone
resorption may represent a late phase of
the Charcot neuroarthropathy disease
process, and a series of immunoinﬂam-
matoryreactionsissuspectedtooccurbe-
fore fragmentation is seen on radiographs
(3,4). Recently, understanding of the ba-
sic patophysiological cascade responsible
fortheinitiationofCharcotneuroarthrop-
athy has evolved (3), and additional in-
vestigation is needed to show whether
medications addressing the imbalance of
RANKL and osteoprotegerin (i.e., tumor
necrosis factor-a inhibitors) could lead
to a faster clinical resolution of acute
Charcot neuroarthropathy. Until then,
the mainstay of the initial management
of acute Charcot neuroarthropathy is
immobilization and ofﬂoading in a plas-
ter cast, with continuous monitoring of
the clinical signs of the activity of the
Charcot neuroarthropathy disease process
(12–14).
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